PURPOSE: Hospital readmissions are often cited as a marker of poor quality of care. Limited data suggest some readmissions may be preventable depending upon definitions and available outpatient support. METHODS: General criteria to define preventable and not preventable admissions were developed before data collection began. The records of sequential nonsurgical oncology readmissions were reviewed independently by two reviewers. When the reviewers disagreed about assigning admissions as preventable or not preventable, a third reviewer was the tie breaker. The reasons for assigning admissions as preventable or not preventable were analyzed. RESULTS: Seventy-two readmissions occurring among 69 patients were analyzed. The first two reviewers agreed that 18 (25%) of 72 were preventable and that 29 (40%) of 72 were not. A third reviewer found four of the split 25 cases to be preventable; therefore, the consensus preventability rate was 22 (31%) of 72. The most common causes of preventability were overwhelming symptoms in patients who qualified for hospice but were not participating in hospice and insufficient communication between patients and the care team about symptom burden. The most common reason for assignment of a not preventable admission was a high symptom burden among patients without strong indications for hospice or for whom aggressive outpatient management was inadequate. The median survival after readmission was 72 days. CONCLUSION: A substantial proportion of oncology readmissions could be prevented with better anticipation of symptoms in high-risk ambulatory patients and enhanced communication about symptom burden between patients and physicians before an escalation that leads to an emergency department visit. Managing symptoms in patients who are appropriate for hospice is challenging. Readmission is a marker of poor prognosis.
PURPOSE: Hospital readmissions are often cited as a marker of poor quality of care. Limited data suggest some readmissions may be preventable depending upon definitions and available outpatient support. METHODS: General criteria to define preventable and not preventable admissions were developed before data collection began. The records of sequential nonsurgical oncology readmissions were reviewed independently by two reviewers. When the reviewers disagreed about assigning admissions as preventable or not preventable, a third reviewer was the tie breaker. The reasons for assigning admissions as preventable or not preventable were analyzed. RESULTS: Seventy-two readmissions occurring among 69 patients were analyzed. The first two reviewers agreed that 18 (25%) of 72 were preventable and that 29 (40%) of 72 were not. A third reviewer found four of the split 25 cases to be preventable; therefore, the consensus preventability rate was 22 (31%) of 72. The most common causes of preventability were overwhelming symptoms in patients who qualified for hospice but were not participating in hospice and insufficient communication between patients and the care team about symptom burden. The most common reason for assignment of a not preventable admission was a high symptom burden among patients without strong indications for hospice or for whom aggressive outpatient management was inadequate. The median survival after readmission was 72 days. CONCLUSION: A substantial proportion of oncology readmissions could be prevented with better anticipation of symptoms in high-risk ambulatory patients and enhanced communication about symptom burden between patients and physicians before an escalation that leads to an emergency department visit. Managing symptoms in patients who are appropriate for hospice is challenging. Readmission is a marker of poor prognosis.
Authors: Kenneth C Anderson; Melissa Alsina; William Bensinger; J Sybil Biermann; Asher Chanan-Khan; Adam D Cohen; Steven Devine; Benjamin Djulbegovic; Cristina Gasparetto; Carol Ann Huff; Madan Jagasia; Bruno C Medeiros; Ruby Meredith; Noopur Raje; Jeffrey Schriber; Seema Singhal; George Somlo; Keith Stockerl-Goldstein; Guido Tricot; Julie M Vose; Donna Weber; Joachim Yahalom; Furhan Yunus Journal: J Natl Compr Canc Netw Date: 2009-10 Impact factor: 11.908
Authors: Gabriel A Brooks; Ling Li; Dhruv B Sharma; Jane C Weeks; Michael J Hassett; K Robin Yabroff; Deborah Schrag Journal: J Natl Cancer Inst Date: 2013-03-12 Impact factor: 13.506
Authors: Michael J Hassett; A James O'Malley; Juliana R Pakes; Joseph P Newhouse; Craig C Earle Journal: J Natl Cancer Inst Date: 2006-08-16 Impact factor: 13.506
Authors: Michael Kolodziej; J Russell Hoverman; Jody S Garey; Janet Espirito; Sheetal Sheth; Aimee Ginsburg; Marcus A Neubauer; Debra Patt; Barry Brooks; Charles White; Mark Sitarik; Roger Anderson; Roy Beveridge Journal: J Oncol Pract Date: 2011-09 Impact factor: 3.840
Authors: Carla N Holcomb; Laura A Graham; Joshua S Richman; Kamal M F Itani; Thomas M Maddox; Mary T Hawn Journal: Ann Surg Date: 2016-05 Impact factor: 12.969
Authors: Jane C Weeks; Paul J Catalano; Angel Cronin; Matthew D Finkelman; Jennifer W Mack; Nancy L Keating; Deborah Schrag Journal: N Engl J Med Date: 2012-10-25 Impact factor: 91.245
Authors: Ezekiel J Emanuel; Yinong Young-Xu; Norman G Levinsky; Gail Gazelle; Olga Saynina; Arlene S Ash Journal: Ann Intern Med Date: 2003-04-15 Impact factor: 25.391
Authors: Vikram Jairam; Victor Lee; Henry S Park; Charles R Thomas; Edward R Melnick; Cary P Gross; Carolyn J Presley; Kerin B Adelson; James B Yu Journal: JAMA Oncol Date: 2019-07-01 Impact factor: 31.777
Authors: Kevin Chen; Keval Desai; Soundari Sureshanand; Kerin Adelson; Jeremy I Schwartz; Cary P Gross; Sarwat I Chaudhry Journal: JCO Oncol Pract Date: 2021-01-08
Authors: Heidi D Klepin; Can-Lan Sun; David D Smith; Rawad Elias; Kelly M Trevino; Ashley Leak Bryant; Daneng Li; Christian Nelson; William P Tew; Supriya G Mohile; Ajeet Gajra; Cynthia Owusu; Cary Gross; Stuart M Lichtman; Vani V Katheria; Hyman B Muss; Andrew E Chapman; Harvey Jay Cohen; Arti Hurria; William Dale Journal: JCO Oncol Pract Date: 2021-04-21
Authors: Anish B Parikh; Xiaobo Zhong; George Mellgard; Qian Qin; Vaibhav G Patel; Bo Wang; Parissa Alerasool; Philip Garcia; Amanda Leiter; Emily J Gallagher; Steven Clinton; Amir Mortazavi; Paul Monk; Edmund Folefac; Ming Yin; Yuanquan Yang; Matthew Galsky; William K Oh; Che-Kai Tsao Journal: Am J Clin Oncol Date: 2021-03-01 Impact factor: 2.787
Authors: Abdallah Y Naser; Hassan Alwafi; Sara Ibrahim Hemmo; Hamzeh Mohammad Alrawashdeh; Jaber S Alqahtani; Saeed M Alghamdi; Moaath K Mustafa Ali Journal: Int J Environ Res Public Health Date: 2022-06-30 Impact factor: 4.614
Authors: Jun Wan; Shiping Xu; Yinqiao Wu; Benyan Wu; Dezhong Joshua Liao; Ningzhi Xu; Gangshi Wang Journal: Support Care Cancer Date: 2018-02-07 Impact factor: 3.603